Di Chen

6.0k total citations · 1 hit paper
96 papers, 4.4k citations indexed

About

Di Chen is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Di Chen has authored 96 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Molecular Biology, 51 papers in Cancer Research and 13 papers in Oncology. Recurrent topics in Di Chen's work include Cancer-related molecular mechanisms research (23 papers), RNA modifications and cancer (21 papers) and Ubiquitin and proteasome pathways (17 papers). Di Chen is often cited by papers focused on Cancer-related molecular mechanisms research (23 papers), RNA modifications and cancer (21 papers) and Ubiquitin and proteasome pathways (17 papers). Di Chen collaborates with scholars based in China, United States and Hong Kong. Di Chen's co-authors include Q. Ping Dou, Kristin R. Landis‐Piwowar, Kenyon G. Daniel, Hai‐long Piao, Tian Xia, Huan Qi, Xiaolong Liu, Qiuzhi Cindy Cui, Chao Duan and Hongxu Liu and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Neuron.

In The Last Decade

Di Chen

93 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The double-edged roles of ROS in cancer prevention and therapy

2021 452 citations Huan Qi, Xiaolong Liu et al. profile →

Peers

Countries citing papers authored by Di Chen

Since Specialization

Citations

This map shows the geographic impact of Di Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Di Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Di Chen more than expected).

Fields of papers citing papers by Di Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Di Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Di Chen. The network helps show where Di Chen may publish in the future.

Co-authorship network of co-authors of Di Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Di Chen. A scholar is included among the top collaborators of Di Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Di Chen. Di Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi-omics approach reveals differences in aroma and metabolic characteristics of two types of jackfruits 2025 ·Food Chemistry X ·Di Chen, Hailong Dong, (unknown), Xiaopeng Wu, (unknown), Weijie Lan, (unknown), Guanhong Tao, (unknown), Chunhua Xu, Wenjiang Dong, Zhihong Xu, (unknown), Lehe Tan	1
2	Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma 2025 ·Molecular Oncology ·Wenjing Wu, Jianchao Wang, (unknown), Xuefeng Wang, (unknown), (unknown), (unknown), Fangfang Chen, Wei Hong, Tianyu Tang, Ying He, Gang Chen, Jianyin Zhou, Hai‐long Piao, Di Chen, Shu‐Yong Lin	1
3	Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy 2024 ·Clinical and Translational Medicine ·Di Chen, Lixia Xu, (unknown), (unknown), Chen Xue	7
4	Writers, readers, and erasers RNA modifications and drug resistance in cancer 2024 ·Molecular Cancer ·Di Chen, Xinyu Gu, (unknown), Lixia Xu, Xueyuan Li, Lixin Wu, (unknown), Peng Gao, Xuqiang Zhu, Dongming Yan, Shaohua Li, Chen Xue	37
5	Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform 2024 ·SHILAP Revista de lepidopterología ·Di Chen, Lixia Xu, (unknown), Weitao Shen, Ziguang Song, Hongjiang Li, Xuqiang Zhu, Xueyuan Li, Lixin Wu, (unknown), (unknown), Jing Yan, Yuting He, Dongming Yan	23
6	Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC 2023 ·European Journal of Medicinal Chemistry ·Di Chen, (unknown), Ziwei Zeng, Jian‐Xiong An, (unknown), (unknown), Lei Chen, Bin He	3
7	Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma 2023 ·Cancer Cell International ·Di Chen, Qiaoqiao Li, (unknown), (unknown), Jianguo Li, Xuqiang Zhu, Hongjiang Li, (unknown), Xianzhi Liu, Dongming Yan	6
8	Midkine noncanonically suppresses AMPK activation through disrupting the LKB1-STRAD-Mo25 complex 2022 ·Cell Death and Disease ·Tian Xia, Di Chen, Xiaolong Liu, Huan Qi, Wen Wang, Huan Chen, Ting Ling, Wuxiyar Otkur, Chen‐Song Zhang, Jongchan Kim, Sheng‐Cai Lin, Hai‐long Piao	17
9	A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome 2022 ·SHILAP Revista de lepidopterología ·Xin Jiang, Yushuang Xu, Di Chen, Mengmeng Wang, Meng-jun Qiu, Lina Xiong, Li Zhang, (unknown), Zhifan Xiong	5
10	Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6 2021 ·ACS Chemical Biology ·(unknown), (unknown), (unknown), Di Chen, (unknown), Yong‐Long Zhao, Yan Li, Ting Liu, Yongjun Li, Yi Wang, Hening Lin, Bin He	47
11	A Novel Autophagy-Related lncRNA Prognostic Signature Associated with Immune Microenvironment and Survival Outcomes of Gastric Cancer Patients 2021 ·International Journal of General Medicine ·Di Chen, Mengmeng Wang, Yushuang Xu, Xin Jiang, Lina Xiong, Li Zhang, (unknown), Zhifan Xiong	8
12	An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases 2019 ·Oncogene ·Di Chen, Zhen Ning, Huan Chen, Chang Lu, Xiaolong Liu, Tian Xia, Huan Qi, Wen Wang, Ting Ling, Xin Guo, Dinesh Singh Tekcham, Xiumei Liu, Jing Liu, Aman Wang, Yan Qiu, Jiwei Liu, Guang Tan, Hai‐long Piao	13
13	Predicting Value of ALCAM as a Target Gene of microRNA-483-5p in Patients with Early Recurrence in Hepatocellular Carcinoma 2018 ·Frontiers in Pharmacology ·Xinyuan Lu, Di Chen, (unknown), Jie Ding, Yingjun Zhao, Qian Zhao, Ming Yao, Zhiao Chen, Xianghuo He, Wen‐Ming Cong	25
14	miR-148b-3p inhibits gastric cancer metastasis by inhibiting the Dock6/Rac1/Cdc42 axis 2018 ·Journal of Experimental & Clinical Cancer Research ·Xiaowei Li, Mingzuo Jiang, Di Chen, Bing Xu, Rui Wang, Yi Chu, (unknown), Lin Zhou, (unknown), Yongzhan Nie, Daiming Fan, Yulong Shang, Kaichun Wu, Jie Liang	43
15	Potential clinical application of lncRNAs in non-small cell lung cancer 2018 ·OncoTargets and Therapy ·Tong Lu, Yuanyong Wang, Di Chen, Jia Liu, Wenjie Jiao	76
16	A LIN28B Tumor-Specific Transcript in Cancer 2018 ·Cell Reports ·Weijie Guo, Zhixiang Hu, (unknown), Yuchen Li, Shengli Li, Qiupeng Zheng, Dongbin Lyu, Di Chen, Tao Yu, Yan Li, Xiaodong Zhu, Jie Ding, Yingjun Zhao, Xianghuo He, Shenglin Huang	26
17	Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin‐6/STAT3 signaling pathway 2017 ·Hepatology ·Jiwei Zhang, Zhe Li, Longzi Liu, Qifeng Wang, Shengli Li, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Shenglin Huang, Yingjun Zhao, Xianghuo He	178
18	Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. 2006 ·Cancer Epidemiology and Prevention Biomarkers ·Di Chen, Qiuzhi Cindy Cui, Huanjie Yang, Q. Ping Dou	17
19	The proteasome as a potential target for novel anticancer drugs and chemosensitizers 2006 ·Drug Resistance Updates ·Kristin R. Landis‐Piwowar, Vesna Milacic, Di Chen, Huanjie Yang, Yunfeng Zhao, Tak Hang Chan, Bing Yan, Q. Ping Dou	123
20	Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells 2005 ·Breast Cancer Research ·Kenyon G. Daniel, Di Chen, (unknown), Qiuzhi Cindy Cui, Fred R. Miller, Q. Ping Dou	286

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact